IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract related to the company’s Phase 2 basket trial (IOB-022/KN-D38) with IO102-IO103 as an investigational agent in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in solid tumors has been accepted for a Mini Oral presentation at the IASLC 2023 World Conference on Lung Cancer (WCLC). The conference is being hosted by the International Association for the Study of Lung Cancer (IASLC) in Singapore from September 9-12, 2023.